e.g. Filippa Pettersson or Cancer Res. 75(6) , 1102-12, (2015) or 10.1002/anie.201600521
Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual β 2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD
A novel class of dual pharmacology bronchodilators targeting both β2-adrenoceptor and PDE4 was designed and synthesised by combining the pharmacophores of salmeterol and roflumilast or phthalazinone. All the compounds exhibited better β2-adrenoceptor agonist activities (pEC50= 8.47–9.20) than the reference compound salmeterol (pEC50= 8.3) and good inhibitory activity on PDE4B2 (IC50= 0.235–1.093 μM).